Published in

Public Library of Science, PLoS ONE, 4(3), p. e1983, 2008

DOI: 10.1371/journal.pone.0001983

Links

Tools

Export citation

Search in Google Scholar

Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials

Journal article published in 2008 by James F. Curtin ORCID, Marianela Candolfi, Tamer M. Fakhouri, Chunyan Liu, Anderson Alden, Matthew Edwards, Pedro R. Lowenstein, Maria G. Castro
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to mediate GBM regression in preclinical models of brain tumors. Clinical trials that combine Treg depletion with tumor vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and improve long term survival in cancer patients.